Authors: EMJ
Support: This content was funded by an educational grant from LivaNova PLC.
Citation: EMJ Neurol. 2024; DOI/10.33590/emjneurol/FLVA6084.
Original citation: EMJ Neurol. 2024; DOI/10.33590/emjneurol/10302650.
Date correction published: 09.05.2024
In the infographic published under EMJ Neurology, the table titled ‘Summary of Key Considerations Relating to Adjunctive Treatment Options for DRE’ information regarding psychiatric warnings was combined with other warnings and precautions in footnotes which can create confusion. It was originally presented that VNS and DBS device product labels ‘did not specify whether DDIs, hepatic/renal function, or psychiatric/fetal risk warnings, are relevant considerations for that product when used for epilepsy indications’, and that the RNS device product label ‘stated an absence of DDIs, no requirement for hepatic/renal adjustment, or that approval is for patients aged ≥18 years (lack of paediatric approval)’. This is incorrect and has now been rectified to indicate that VNS and RNS do not have psychiatric warnings stated in the warnings and precautions section of their approved product labels, and all other drugs and devices included in the table have psychiatric warnings stated on their product labels. To provide clarity, a new footnote has been added to the infographic with a solid diamond to indicate those therapies with specific warnings and precautions and an open diamond for those therapies without. Please see individual product labels and instructions for use for further information and details.
